Leaders in Pharmaceutical Business Intelligence (LPBI) Group

An Evolving Paradigm of Drug Discovery – Externalization, Virtualization, De-virtualization, Contract Research & Strategic Partnerships, 2016 MassBio Annual Meeting  03/31/2016 8:00 AM – 04/01/2016 3:00 PM Royal Sonesta Hotel, Cambridge, MA

Leaders in Pharmaceutical Business Intelligence (LPBI) Group, Boston

covers in REAL TIME

2016 MassBio Annual Meeting  03/31/2016 8:00 AM – 04/01/2016 3:00 PM Royal Sonesta Hotel, Cambridge, MA

 In Attendance, steaming LIVE using Social Media

Aviva Lev-Ari, PhD, RN

Editor-in-Chief

http://pharmaceuticalintelligence.com

Director & Founder

Leaders in Pharmaceutical Business Intelligence (LPBI) Group, Boston

https://www.massbio.org/events/2016-massbio-annual-meeting-1120

2016 MassBio Annual Meeting  03/31/2016 8:00 AM – 04/01/2016 3:00 PM Royal Sonesta, Cambridge MA

http://pharmaceuticalintelligence.com/2016/03/02/2016-massbio-annual-meeting-03312016-800-am-04012016-300-pm-royal-sonesta-cambridge-ma/

Plenary Session:  An Evolving Paradigm of Drug Discovery – Externalization, Virtualization, De-virtualization, Contract Research & Strategic Partnerships

• Ryan Brady, Vice President, Business Development, Evotec (Moderator)

1. 65% of Phase III were source externaly – CHANGING PARADIGM OF DRUG DISCOVERY
2. early stage researcg collabration – how you become partner of choice
3. Not invented here syndrom — exist
4. facilitate conversation among Scientist – break barriers of 3, above
5. Partner of CHoice – How you motivate people?

• Brian Bronk, Principal, Sunrise Ventures, Sanofi Global R&D

1. company co-creation
2. strategic alliance
3. Sanofi – 50% pipeline from external sources
4. collaboration wiht Evotec
5. Biotech – travel to partner often
6. Sunrise portfolio companies: ALl companies are encourage to be autonomous
7. Sanofi and Evotec – both parties will benefit Pharma vs Biotech

• Arpita Maiti, Director, External R&D Innovation, Inflammation & Immunology, Pfizer

1. Embedded Core  – 40% of current portfolio from external sources
2. Evotec collaboration
3. Cultural component Pfizer encourage collaboration
4. Being in it together, Pfizer care, believe in process
5. Process – Steering committees, building personal relations
6. If a small company takes to FDA less scrutany than by Pfizer going to FDA

• Jeff Nye, Vice President, Neuroscience Innovation, Johnson & Johnson

1. Externalization model very successful
2. neuropharmacology R&D externalize to Academic Consorsium
3.  Selling internally is hard, buying expernally is easy
4. SanDiedo rent place in La Jolla – build Ecosystmes around J&J
5. build a company, on the Board, expertise advice, no tied relations — third party comes and walk away with this comapny
6. IP Leakage is a risk,  firewalls considered
7. Small companies are cost effective
8. AT Phase III and at Commercialization Pfizer can contribute the R&D at small partners is cheaper and faster
9. Secrecy in Academai
10. ClinicalTrials.gov

• Samantha Truex, Chief Business Officer, Padlock Therapeutics, acquired by BMS 4/1/2016

1. small molecule – outsourced
2. biologics – outsourced
3. Biogen started an incubator – failed because requested option to acquire companie
4. complex assays  – required the lab
5. Samples stuck in customes
6. Platform company – Provide services — use part of libraries fo reach client
7. Recommendations from partners

• Ankit Mahadevia, CEO Spera

1. Nothing was invented here
2. virtual model, assays are reproduceable
3. complex biology – done internally in a new lab built
4. Evotec – Data is our with a collaborator
5. Virtualization, borrow, collaborative in quick efficient way
6. rent space in Cambridge is very expensive
7. Biotech: CHoose the best for every function, no routine requires specializing in one function